Trial Profile
A repeat dose study of RTU-1096 to assess its safety, tolerability and pharmacokinetics.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 May 2015
Price :
$35
*
At a glance
- Drugs RTU 1096 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors R-Tech Ueno
- 26 May 2015 New trial record